image credit: Adobe Stock

Gates Foundation supports HIV and malaria research

January 14, 2022


The new commitment from the Bill & Melinda Gates Foundation supports the development of Vir Biotech’s ‘vaccinal antibody’ technology, a significant tool in combatting global infectious diseases. Vir’s antibody research initiative aims for a functional cure for HIV and for the prevention of malaria.

The expansion of Vir’s partnership with the foundation will include the advancement of innovative platform technologies for the development of ‘broadly neutralising antibodies’. These antibodies will aim to provide a ‘vaccinal effect’ for the treatment of HIV and the prevention of malaria. The programme will combine Vir’s extensive expertise of viruses and immune systems with the Gates Foundation’s established global health leadership to address two of the world’s most challenging infectious diseases.

Read More on Pharma Times